Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk.

Sone T, Ito M, Fukunaga M, Tomomitsu T, Sugimoto T, Shiraki M, Yoshimura T, Nakamura T.

Bone. 2014 Jul;64:75-81. doi: 10.1016/j.bone.2014.04.004. Epub 2014 Apr 13.

2.

Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.

Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ.

Bone. 2005 Jun;36(6):948-58.

PMID:
15878318
3.

The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT.

Ito M, Oishi R, Fukunaga M, Sone T, Sugimoto T, Shiraki M, Nishizawa Y, Nakamura T.

Osteoporos Int. 2014 Mar;25(3):1163-72. doi: 10.1007/s00198-013-2596-y. Epub 2013 Dec 18.

4.

Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial.

Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, Harper KD.

Osteoporos Int. 2006;17(4):575-86. Epub 2006 Jan 4.

PMID:
16392026
5.

Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.

Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.

Curr Med Res Opin. 2013 Mar;29(3):195-203. doi: 10.1185/03007995.2012.761956. Epub 2013 Jan 17.

PMID:
23259702
6.

The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis.

Beck TJ, Fuerst T, Gaither KW, Sutradhar S, Levine AB, Hines T, Yu CR, Williams R, Mirkin S, Chines AA.

Bone. 2015 Aug;77:115-9. doi: 10.1016/j.bone.2015.04.027. Epub 2015 Apr 23.

PMID:
25917574
7.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.

J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.

8.

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.

Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.

J Bone Miner Res. 2005 Sep;20(9):1507-13. Epub 2005 May 2.

9.

Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.

Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA.

J Bone Miner Res. 2005 Sep;20(9):1525-32. Epub 2005 May 9.

10.

[Once-weekly teriparatide treatment on osteoporosis].

Nakano T.

Clin Calcium. 2014 Jan;24(1):100-5. doi: CliCa1401100105. Review. Japanese.

PMID:
24369286
11.

Hip cortical thickness assessment in postmenopausal women with osteoporosis and strontium ranelate effect on hip geometry.

Briot K, Benhamou CL, Roux C.

J Clin Densitom. 2012 Apr-Jun;15(2):176-85. doi: 10.1016/j.jocd.2011.11.006. Epub 2012 Feb 9.

PMID:
22321661
12.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
13.

Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.

Krege JH, Wan X.

Bone. 2012 Jan;50(1):161-4. doi: 10.1016/j.bone.2011.10.018. Epub 2011 Oct 22.

PMID:
22036910
14.
15.

Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.

Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.

J Clin Endocrinol Metab. 2012 Sep;97(9):3097-106. doi: 10.1210/jc.2011-3479. Epub 2012 Jun 20.

PMID:
22723322
16.

Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.

Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.

J Assoc Physicians India. 2008 Jun;56:418-24.

PMID:
18822620
17.

FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.

Harvey NC, Kanis JA, Odén A, Burge RT, Mitlak BH, Johansson H, McCloskey EV.

Osteoporos Int. 2015 Nov;26(11):2677-84. doi: 10.1007/s00198-015-3173-3. Epub 2015 Jun 20.

18.

Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.

Han SL, Wan SL.

Int J Clin Pract. 2012 Feb;66(2):199-209. doi: 10.1111/j.1742-1241.2011.02837.x. Review.

PMID:
22257045
19.

Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.

Tanaka S, Kuroda T, Sugimoto T, Nakamura T, Shiraki M.

Curr Med Res Opin. 2014 May;30(5):931-6. doi: 10.1185/03007995.2013.879440. Epub 2014 Jan 13.

PMID:
24392946
20.

Femoral strength in osteoporotic women treated with teriparatide or alendronate.

Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.

Bone. 2012 Jan;50(1):165-70. doi: 10.1016/j.bone.2011.10.002. Epub 2011 Oct 17.

PMID:
22015818

Supplemental Content

Support Center